8.3 Postpartum Coagulopathies (DIC, ITP) & Venous Thromboembolism (DVT, PE)

8.3 Postpartum Coagulopathies (DIC, ITP) & Venous Thromboembolism (DVT, PE)

Core Focus: Maternal-newborn nurses must understand the consumptive pathophysiology and laboratory diagnosis of Disseminated Intravascular Coagulation (DIC), differentiate benign gestational thrombocytopenia from autoimmune Immune Thrombocytopenic Purpura (ITP), evaluate puerperal venous thromboembolism (DVT and pulmonary embolism) via Virchow's triad, and implement evidence-based anticoagulation protocols that ensure maternal-infant lactation safety.

---

1. Disseminated Intravascular Coagulation (DIC) in the Puerperium

Disseminated Intravascular Coagulation (DIC) is an acquired, secondary consumptive coagulopathy. It is never an isolated, primary medical illness; rather, it represents the catastrophic end-stage pathway of an underlying obstetric trigger that introduces tissue factor (thromboplastin) or bacterial endotoxins into the maternal circulation.

Pathophysiologic Cascade of Obstetric DIC:
Tissue Factor Release ──> Massive Uncontrolled Thrombin Generation ──>
Diffuse Microvascular Fibrin Thrombi ──> Ischemic End-Organ Damage ──>
Exhaustion of Platelets & Clotting Factors (Consumption) ──>
Excessive Secondary Fibrinolysis (Elevated FDPs/D-Dimer) ──> Catastrophic Systemic Bleeding

The Pathophysiologic Paradox

The hallmark of DIC is a life-threatening paradox: widespread microvascular thrombosis occurs simultaneously with massive, uncontrolled systemic bleeding:

1. Diffuse Thrombus Formation: Excessive circulating thrombin converts fibrinogen into widespread microvascular fibrin networks throughout the capillary beds of the kidneys, lungs, liver, and brain, precipitating ischemic tissue necrosis and multi-organ failure.
2. Consumptive Depletion: Rapid, widespread micro-clotting completely consumes systemic reserves of platelets, fibrinogen, prothrombin, and factors V and VIII faster than the liver and bone marrow can synthesize them.
3. Secondary Hyperfibrinolysis: In response to extensive intravascular thrombosis, endothelial cells release massive quantities of tissue plasminogen activator (tPA). Plasmin lyses fibrin clots, generating high concentrations of fibrin degradation products (FDPs) and D-dimers. These degradation fragments act as potent circulating anticoagulants, directly inhibiting platelet aggregation and preventing normal fibrin polymerization.

Major Obstetric Triggers for DIC

• Placental Abruption (Abruptio Placentae): The single most common obstetric cause of DIC (~50% of cases). Retroplacental hematoma formation and decidual disruption release massive quantities of procoagulant tissue factor directly into maternal venous sinuses.
• Amniotic Fluid Embolism (AFE / Anaphylactoid Syndrome of Pregnancy): Entry of amniotic fluid—rich in fetal squamous cells, procoagulants, and tissue factor—into maternal circulation triggers sudden cardiopulmonary collapse followed by profound, explosive DIC in >80% of survivors.
• Severe Preeclampsia & HELLP Syndrome: Widespread vascular endothelial activation, microangiopathic hemolytic destruction of erythrocytes, and platelet activation.
• Postpartum Sepsis / Septic Shock: Gram-negative lipopolysaccharides (endotoxins) stimulate inflammatory cytokine release (IL-1, TNF-alpha), activating tissue factor and depressing natural anticoagulant pathways (Protein C and Antithrombin).
• Prolonged Retained Intrauterine Fetal Demise (IUFD >4–6 Weeks): Degenerating fetal tissues release thromboplastic enzymes across the placenta into maternal circulation.
• Massive Hemorrhage / Dilutional Coagulopathy: Extensive blood loss combined with rapid, aggressive crystalloid volume replacement without balanced blood factors dilutes coagulation proteins and accelerates the "lethal triad" of hypothermia, acidosis, and coagulopathy.

Clinical Manifestations of DIC

• Spontaneous Bleeding from Multiple Unrelated Sites: Continuous oozing from venipuncture sites, peripheral IV lines, arterial lines, epidural/spinal needle insertion wounds, surgical incisions, and episiotomy repairs.
• Mucosal & Internal Bleeding: Spontaneous gingival bleeding (gums), epistaxis, frank hematuria, and gastrointestinal bleeding.
• Cutaneous Findings: Widespread petechiae, purpura, and expansive ecchymosis under blood pressure cuffs or at pressure points.
• Vaginal Bleeding: Continuous, profuse, thin, watery lochia that completely fails to form clots.
• Microvascular Ischemic Signs: Acute renal failure with oliguria (<30 mL/hr) from renal cortical necrosis, jaundice from hepatic ischemia, pulmonary dysfunction, and neurological changes (confusion, lethargy, seizures).

Diagnostic Laboratory Coagulation Profile

[!IMPORTANT] THE FIBRINOGEN EXAM ALERT: In normal late pregnancy, physiological hyperfibrinogenemia elevates plasma fibrinogen to 300 to 600 mg/dL to protect against delivery hemorrhage. Therefore, a fibrinogen value of 200 mg/dL—which is considered completely "normal" in a non-pregnant adult—represents critical, life-threatening depletion in a bleeding obstetric patient and is a sensitive harbinger of consumptive DIC!

Bedside Clot Observation Test (Lee-White / Red-Top Tube Test)

When laboratory turnaround times are prolonged, nurses can perform an immediate bedside whole blood clot test:

• Draw 5 mL of maternal venous blood into a plain glass tube with no additives (red-top tube).
• Hold the tube undisturbed at bedside for 6 to 10 minutes.
• Normal Response: A firm, solid clot forms within 6 to 10 minutes and resists inversion.
• DIC Finding: Blood remains completely unclotted after 10 to 15 minutes, or forms a soft, fragile, friable clot that completely dissolves within 30 to 60 minutes due to rampant hyperfibrinolysis.

Resuscitation & Component Replacement Protocols

1. Eliminate the Underlying Trigger: Delivery of the infant and placenta in abruption, evacuation of retained placental tissue, aggressive surgical source control, or intravenous broad-spectrum antibiotics for sepsis.
2. Targeted Transfusion Therapy:
   • Cryoprecipitate: The treatment of choice for hypofibrinogenemia. A 10-unit pool provides ~2 to 3 grams of concentrated fibrinogen, factor VIII, and von Willebrand factor, raising plasma fibrinogen by 50 to 70 mg/dL. Target fibrinogen >150 to 200 mg/dL.
   • Fresh Frozen Plasma (FFP): Administer 10 to 15 mL/kg (typically 2 to 4 units) to replenish factor V, factor VIII, and prothrombin, reversing prolonged PT/INR and aPTT.
   • Platelets: Transfuse 1 apheresis unit (or 6-pack pooled platelets) when platelet count drops <50,000/mcL in the presence of active bleeding.
   • Packed Red Blood Cells (PRBCs): Maintain oxygen-carrying capacity with a target hemoglobin >8 g/dL (hematocrit >24%).
3. Maintain Physiological Homeostasis: Ensure core temperature ≥36.0°C (hypothermia inactivates coagulation enzymes), correct acidosis (target arterial pH ≥7.25), and support renal perfusion (urine output ≥30 mL/hr).

---

2. Differentiating Postpartum Thrombocytopenias

Thrombocytopenia (platelet count <150,000/mcL) is the second most common hematologic abnormality in pregnancy. Maternal-newborn nurses must rapidly distinguish between benign physiological drops and serious autoimmune or microangiopathic pathologies:

[!NOTE] ITP and Neonatal Safety: Because maternal antiplatelet IgG antibodies readily cross the placenta, the neonate is at significant risk for passive autoimmune thrombocytopenia, which reaches its lowest nadir on days 2 to 5 of life. Avoid fetal scalp electrodes and operative vacuum delivery, and obtain immediate umbilical cord platelet counts followed by serial neonatal platelet monitoring to prevent occult intracranial hemorrhage.

---

3. Venous Thromboembolism (VTE) in the Puerperium: DVT and PE

Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a leading cause of maternal morbidity and mortality in industrialized nations.

Postpartum VTE Risk Profile:
Pregnancy: 5-fold increase in VTE risk compared to non-pregnant baseline.
Postpartum (Puerperium): 20- to 80-fold increase during the first 6 weeks post-birth.
Peak Risk Window: The first 1 to 2 weeks postpartum represents the period of maximum vulnerability.

Virchow's Triad in the Postpartum Period

1. Hypercoagulability: An evolutionary physiologic adaptation designed to limit blood loss at placental separation. The puerperium features elevated procoagulant factors (fibrinogen, factors VII, VIII, X, and von Willebrand factor), decreased anticoagulants (protein S activity drops by 40–50%; acquired activated protein C resistance), and elevated plasminogen activator inhibitors (PAI-1 and PAI-2).
2. Venous Stasis: The gravid uterus mechanically compresses the inferior vena cava and left common iliac vein, decreasing lower extremity venous flow velocity by 50%. Postpartum pelvic venous capacity remains dilated, while bed rest, operative recovery, and decreased mobility exacerbate blood pooling.
3. Vascular Endothelial Injury: Labor and birth produce direct mechanical trauma to pelvic and uterine vessels during vaginal delivery, vacuum extraction, or cesarean hysterotomy and surgical tissue manipulation.

---

Deep Vein Thrombosis (DVT)

Clinical Presentation

• Unilateral leg pain, calf tenderness, localized erythema, and increased skin warmth.
• Unilateral lower extremity edema: A calf circumference discrepancy >2 cm measured at the same anatomical distance (10 cm below the tibial tuberosity) is clinically significant.

Left Lower Extremity Predominance

More than 80% to 90% of lower extremity DVTs in pregnancy and the puerperium occur in the left leg.

• Anatomical Basis (May-Thurner Anatomy): The left common iliac vein is compressed against the fifth lumbar vertebra by the overlying right common iliac artery. This natural anatomical compression, compounded by the dextro-rotated postpartum uterus, produces severe focal venous stasis in the left pelvic and femoral outflow tract.

[!WARNING] HOMAN'S SIGN IS CONTRAINDICATED: Historically, Homan's sign (pain in the calf upon abrupt dorsiflexion of the foot) was used to screen for DVT. Modern clinical evidence confirms that Homan's sign is neither sensitive nor specific (>50% false-positive and false-negative rates). Furthermore, the mechanical force of aggressive dorsiflexion risks dislodging an unstable, fresh deep vein thrombus, transforming an isolated DVT into a fatal pulmonary embolism. Homan's sign is not recommended and should never be performed.

Diagnostic Gold Standard

• Compression Ultrasonography (CUS) with duplex color Doppler of the proximal lower extremity veins. Inability to compress the venous lumen under direct transducer probe pressure confirms the presence of an intraluminal thrombus.

---

Pulmonary Embolism (PE)

Pulmonary embolism occurs when a thrombus dislodges from deep pelvic or lower extremity veins, traverses the inferior vena cava and right heart, and lodges in the pulmonary arterial tree.

Clinical Manifestations

• Sudden, abrupt onset of dyspnea (present in >80% of cases)
• Pleuritic chest pain (worsened by deep inspiration)
• Tachypnea (respiratory rate >20–24 breaths/min) and tachycardia (heart rate >100 bpm)
• Non-productive cough, hemoptysis (coughing blood, indicating pulmonary infarction), diaphoresis, syncope
• Profound sense of impending doom, severe apprehension, lightheadedness
• Hypoxemia: SpO2 <95% on room air; arterial blood gas reveals hypoxemia, hypocapnia, and acute respiratory alkalosis

Diagnostic Workup

• Immediate supplemental oxygen and continuous pulse oximetry.
• Definitive Diagnostic Imaging: Computed Tomography Pulmonary Angiography (CTPA) is the first-line imaging modality of choice, providing rapid, definitive visualization of filling defects in pulmonary arterial branches with minimal maternal-fetal radiation exposure. Ventilation-Perfusion (V/Q) scanning is an alternative when CTPA is contraindicated (e.g., severe renal impairment or contrast dye allergy).

---

4. Anticoagulation Management & Lactation Safety

Anticoagulation Drug of Choice in Postpartum:
Low-Molecular-Weight Heparin (LMWH / Enoxaparin)
1 mg/kg subcutaneously every 12 hours (therapeutic dosing)

Pharmacologic Protocols

1. Low-Molecular-Weight Heparin (LMWH / Enoxaparin): First-line therapy for acute postpartum VTE. LMWH offers superior bioavailability, predictable dose-response kinetics, a lower incidence of Heparin-Induced Thrombocytopenia (HIT <0.1%), lower risk of osteoporosis, and eliminates the need for routine laboratory aPTT monitoring. (Anti-Factor Xa levels are monitored only in severe obesity or renal impairment).
2. Unfractionated Heparin (UFH): Administered as an IV infusion titrated to maintain aPTT at 1.5 to 2.5 times the laboratory baseline control. UFH is preferred in clients with severe renal failure (creatinine clearance <30 mL/min) or when immediate reversal may be required for urgent surgical intervention (rapidly neutralized with protamine sulfate).
3. Postpartum Warfarin (Coumadin) Bridging: While strictly contraindicated during pregnancy due to teratogenicity (warfarin embryopathy), Warfarin can be initiated in the postpartum period:
   • Bridging Protocol: LMWH or UFH must be co-administered with oral Warfarin for at least 5 consecutive days AND until the INR is therapeutic (2.0 to 3.0) for two consecutive days. Co-administration is mandatory because Warfarin initially suppresses protein C and protein S faster than procoagulant factors, creating a transient paradoxical hypercoagulable state.

• Duration of Anticoagulation: Continued for a minimum of 3 to 6 months total, and for at least 6 weeks postpartum, whichever duration is longer.

Lactation Safety: The Breastfeeding Rules

[!IMPORTANT] BREASTFEEDING & ANTICOAGULATION SAFETY:

• Low-Molecular-Weight Heparin (Enoxaparin): Does NOT pass into breast milk due to its high molecular weight and dense negative electrical charge. Any minuscule trace amounts swallowed by the infant are completely inactivated and digested by neonatal gastric acid and proteases. COMPLETELY SAFE FOR BREASTFEEDING.
• Unfractionated Heparin (UFH): Does NOT pass into breast milk. COMPLETELY SAFE FOR BREASTFEEDING.
• Warfarin (Coumadin): Tightly bound to maternal plasma albumin (>99%) and does not transfer into human milk in clinically measurable amounts. Neonatal coagulation parameters remain entirely unaffected. COMPLETELY SAFE FOR BREASTFEEDING.
• Direct Oral Anticoagulants (DOACs - Apixaban, Rivaroxaban, Dabigatran): Secreted into breast milk in animal and human studies with unknown neonatal clearance kinetics. DOACs are NOT recommended during lactation; mothers requiring anticoagulation while breastfeeding must receive LMWH or Warfarin.